Analysis of Circulating Endostatin and Vascular Endothelial Growth Factor in Patients with Pituitary Adenoma Treated by Stereotactic Radiosurgery: A Preliminary Study

Overview

Journal Brain Tumor Res Treat

Date 2015 Nov 26

PMID 26605263

Citations 4

Authors

Kyung-Min Lee

Seong-Hyun Park

Ki-Su Park

Jeong-Hyun Hwang

Sung-Kyoo Hwang

Affiliations

Soon will be listed here.

Abstract

Background: The purpose of this study was to investigate plasma levels of endostatin and vascular endothelial growth factor (VEGF) in normal subjects and in patients with pituitary adenoma and to evaluate change in these levels following stereotactic radiosurgery (SRS) for pituitary adenoma.

Methods: Peripheral venous blood was collected from five patients with pituitary adenoma before SRS using Gamma Knife and at the 1 week and 1 month follow-up visits. Plasma endostatin and VEGF levels were measured using commercially available enzyme-linked immunosorbent assay kits. Peripheral blood samples were obtained from 10 healthy volunteers as controls.

Results: Mean baseline plasma endostatin level (105.3 ng/mL, range, 97.0-120.2 ng/mL) in patients with pituitary adenoma was higher than that of the healthy controls (86.6 ng/mL, range, 71.3-98.2 ng/mL) (p=0.001). Mean plasma VEGF level was 89.5 pg/mL (range, 24.1-171.8 pg/mL) in patients with pituitary adenoma at baseline and 29.3 pg/mL (range, 9.2-64.3 pg/mL) in the control group (p=0.050). Plasma endostatin level changed to 106.6 ng/mL 1 week after SRS and decreased to 95.9 ng/mL after 1 month. Plasma VEGF level following SRS decreased to 74.1 pg/mL after 1 week and 79.0 pg/mL after 1 month. There was a trend toward decreased plasma endostatin and VEGF concentrations 1 month after SRS compared to baseline levels (p=0.195, p=0.812, respectively).

Conclusion: Plasma endostatin and VEGF levels in patients with pituitary adenoma were significantly elevated over controls at baseline, which decreased from baseline to 1 month after SRS for pituitary adenomas.

Citing Articles

Role of Tumor Microenvironment in Pituitary Neuroendocrine Tumors: New Approaches in Classification, Diagnosis and Therapy.

Tapoi D, Popa M, Tanase C, Derewicz D, Gheorghisan-Galateanu A Cancers (Basel). 2023; 15(21).

PMID: 37958474 PMC: 10649263. DOI: 10.3390/cancers15215301.

Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Ghadir M, Khamseh M, Panahi-Shamsabad M, Ghorbani M, Akbari H, Mehrjardi A Endocrine. 2020; 69(3):596-603.

PMID: 32656696 DOI: 10.1007/s12020-020-02366-6.

VEGF, VEGF165b and EG-VEGF expression is specifically related with hormone profile in pituitary adenomas.

Corlan A, Cimpean A, Melnic E, Raica M, Sarb S Eur J Histochem. 2019; 63(1).

PMID: 30838843 PMC: 6406074. DOI: 10.4081/ejh.2019.3010.

Landscape of Molecular Events in Pituitary Apoplexy.

Gupta P, Dutta P Front Endocrinol (Lausanne). 2018; 9:107.

PMID: 29615979 PMC: 5869273. DOI: 10.3389/fendo.2018.00107.

References

Lee C, Kano H, Yang H, Xu Z, Yen C, Chung W . Initial Gamma Knife radiosurgery for nonfunctioning pituitary adenomas. J Neurosurg. 2014; 120(3):647-54. DOI: 10.3171/2013.11.JNS131757. View

Stepien H, Kolomecki K, Pasieka Z, Komorowski J, Stepien T, Kuzdak K . Angiogenesis of endocrine gland tumours--new molecular targets in diagnostics and therapy. Eur J Endocrinol. 2002; 146(2):143-51. DOI: 10.1530/eje.0.1460143. View

Kraft A, Weindel K, Ochs A, Marth C, Zmija J, Schumacher P . Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999; 85(1):178-87. View

Gruszka A, Kunert-Radek J, Pawlikowski M, Stepien H . Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with pituitary adenomas. Pituitary. 2005; 8(2):163-8. DOI: 10.1007/s11102-005-5258-z. View

OSullivan E, Woods C, Glynn N, Behan L, Crowley R, OKelly P . The natural history of surgically treated but radiotherapy-naïve nonfunctioning pituitary adenomas. Clin Endocrinol (Oxf). 2009; 71(5):709-14. DOI: 10.1111/j.1365-2265.2009.03583.x. View

Zucker S, Mirza H, CONNER C, Lorenz A, Drews M, Bahou W . Vascular endothelial growth factor induces tissue factor and matrix metalloproteinase production in endothelial cells: conversion of prothrombin to thrombin results in progelatinase A activation and cell proliferation. Int J Cancer. 1998; 75(5):780-6. DOI: 10.1002/(sici)1097-0215(19980302)75:5<780::aid-ijc19>3.0.co;2-a. View

Feldman A, Tamarkin L, Paciotti G, SIMPSON B, Linehan W, Yang J . Serum endostatin levels are elevated and correlate with serum vascular endothelial growth factor levels in patients with stage IV clear cell renal cancer. Clin Cancer Res. 2001; 6(12):4628-34. View

Paez Pereda M, Ledda M, Goldberg V, Chervin A, Carrizo G, Molina H . High levels of matrix metalloproteinases regulate proliferation and hormone secretion in pituitary cells. J Clin Endocrinol Metab. 2000; 85(1):263-9. DOI: 10.1210/jcem.85.1.6248. View

Nonoguchi N, Miyatake S, Fukumoto M, Furuse M, Hiramatsu R, Kawabata S . The distribution of vascular endothelial growth factor-producing cells in clinical radiation necrosis of the brain: pathological consideration of their potential roles. J Neurooncol. 2011; 105(2):423-31. DOI: 10.1007/s11060-011-0610-9. View

10.

Sanchez-Ortiga R, Sanchez-Tejada L, Moreno-Perez O, Riesgo P, Niveiro M, Alfonso A . Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrence. Pituitary. 2012; 16(3):370-7. DOI: 10.1007/s11102-012-0434-4. View

11.

Sheehan J, Starke R, Mathieu D, Young B, Sneed P, Chiang V . Gamma Knife radiosurgery for the management of nonfunctioning pituitary adenomas: a multicenter study. J Neurosurg. 2013; 119(2):446-56. DOI: 10.3171/2013.3.JNS12766. View

12.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

13.

Vermeulen S, Young R, Li F, Meier R, Raisis J, Klein S . A comparison of single fraction radiosurgery tumor control and toxicity in the treatment of basal and nonbasal meningiomas. Stereotact Funct Neurosurg. 2000; 72 Suppl 1:60-6. DOI: 10.1159/000056440. View

14.

Komorowski J, Jankewicz J, Stepien H . Vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) and soluble interleukin-2 receptor (sIL-2R) concentrations in peripheral blood as markers of pituitary tumours. Cytobios. 2000; 101(398):151-9. View

15.

Feldman A, Alexander Jr H, Bartlett D, Kranda K, Miller M, Costouros N . A prospective analysis of plasma endostatin levels in colorectal cancer patients with liver metastases. Ann Surg Oncol. 2001; 8(9):741-5. DOI: 10.1007/s10434-001-0741-x. View

16.

Turner H, Harris A, Melmed S, Wass J . Angiogenesis in endocrine tumors. Endocr Rev. 2003; 24(5):600-32. DOI: 10.1210/er.2002-0008. View